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Abstract 
Undifferentiated nasopharyngeal carcinoma (NPC) is a cancer with high metastatic potential that is 
consistently associated with Epstein-Barr virus (EBV) infection. In this study, we have investigated 
the functional contribution of sphingosine-1-phosphate (S1P) signalling to the pathogenesis of 
NPC. We show that EBV infection or ectopic expression of the EBV-encoded latent genes 
(EBNA1, LMP1 and LMP2A) can up-regulate sphingosine kinase 1 (SPHK1), the key enzyme that 
produces S1P, in NPC cell lines. Exogenous addition of S1P promotes the migration of NPC cells 
through the activation of AKT; shRNA knockdown of SPHK1 resulted in a reduction in the levels 
of activated AKT and inhibition of cell migration. We also show that the S1P receptor 3 (S1PR3) is 
over-expressed in EBV-positive NPC patient-derived xenografts and a subset of primary NPC 
tissues and that knockdown of S1PR3 suppressed the activation of AKT and the S1P-induced 
migration of NPC cells. Taken together, our data point to a central role for EBV in mediating the 
oncogenic effects of S1P in NPC and identify S1P signalling as a potential therapeutic target in this 
disease. 
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Introduction 
Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that is exceptionally prevalent in 
Southern China and South East Asia [1, 2]. Approximately 75% of NPC patients present with late 
stage disease and approximately 30% of these patients develop distant metastases post therapy [1, 
3]. Existing treatment for advanced disease is limited to concurrent chemoradiotherapy and 
unfortunately, due to the location of tumours in close proximity to many vital organs in the head 
and neck region, most survivors of NPC have an impaired health-related quality of life [4, 5]. A 
deeper understanding of the molecular basis of NPC is required to inform innovations in the 
therapeutic approach.  
 
Undifferentiated NPC is invariably associated with Epstein-Barr virus (EBV) infection [6]. 
EBV latent gene expression in NPC is restricted to Epstein-Barr nuclear antigen 1 (EBNA1), latent 
membrane proteins (LMP 1 and LMP2), EBV-encoded RNAs (EBERs) and BamHI-A transcripts. 
Although the exact pathogenic role of EBV in NPC tumorigenesis remains to be fully elucidated, it 
is well established that the expression of these EBV latent genes results in the perturbation of many 
cellular processes, which leads to the development of NPC.  
 
Given that distant metastasis is a major cause of death for NPC patients, we focused on the 
possibility that sphingosine-1-phosphate (S1P) signalling, a pathway that has been shown to 
promote cancer cell migration and invasion [7], could be involved in the pathogenesis of NPC. S1P 
is a bioactive lipid mainly produced by sphingosine kinase 1 (SPHK1) [8], an enzyme that is 
activated following phosphorylation at Ser225 by extracellular signal-regulated kinase 1/2 (ERK 
1/2) and translocated to the plasma membrane to generate S1P [9].  High expression of SPHK1 was 
shown to be associated with poor prognosis in NPC [10], but the downstream biological 
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consequences of elevated SPHK1 in NPC cells have not been studied. The pro-oncogenic effects of 
S1P have been suggested to be mainly a consequence of alterations in the expression or function of 
one or more of five known G protein-coupled receptors (GPCR), S1PR1-5 [11]. We were 
particularly interested to explore if the aberrant activation of the SPHK1/S1P/S1PR axis could 
contribute to the migratory potential of NPC. We show for the first time that EBV infection 
enhances the expression of SPHK1 in NPC cells, and S1P induces NPC cell migration by activating 
AKT through S1PR3. 
 
Materials and Methods 
Cell lines, xenografts and tissue samples 
The cell lines used in this study included: an immortalised nasopharyngeal epithelial cell line, 
NP69; eight NPC-derived cell lines, of which seven are EBV-negative (CNE1, CNE2, HK1, 
HONE1, SUNE1, TW01, TW04) and one of which is EBV-positive (C666-1). NPC cells stably 
infected with a recombinant EBV (Akata strain) or expressing individual EBV-encoded latent genes 
were generated, as previously described [12]. Four NPC patient-derived EBV-positive xenografts 
(xeno-2117, xeno-666, C15 and C17) were used in this study [13-15]. Paraffin-embedded archival 
NPC and non-malignant nasopharyngeal tissue samples were obtained from the tissue bank of 
Department of Anatomical and Cellular Pathology at the Prince of Wales Hospital, The Chinese 
University of Hong Kong (CUHK). The study protocol was approved by the Clinical Research 
Ethics Committee of the CUHK.  All NPC samples were non-keratinising EBER-positive. The 
study protocol was approved by the Joint Chinese University of Hong Kong ± New Territories East 
Cluster Clinical Research Ethics Committee, Hong Kong. The clinical characteristics of the NPC 
samples are listed in Supplementary Table 1. 
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Quantitative real-time PCR (Q-PCR) 
Total RNA was extracted using a RNeasy Mini Kit (Qiagen, UK) and subjected to reverse 
transcription using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA). Q-
PCR was performed in triplicate using the ABI Prism 7000 Sequence Detection System and 
TaqMan Gene Expression Assays (SPHK1: Hs00184211_m1; S1PR3: Hs00245464_s1; Applied 
Biosystems, USA). GAPDH was amplified in the same reaction to serve as an internal control for 
normalization. Fold changes in gene expression were measured using the comparative threshold 
cycle method (''Ct). 
 
Western blotting   
Cells were lysed in ice-cold NP40 lysis buffer [150mM NaCl, 1% IGEPAL® CA-630, 50mM Tris-
HCl (pH 8.0)] containing protease inhibitors (cocktail set III; Calbiochem, Merck Millipore) and 
phosphatase inhibitors (Halt phosphatase inhibitor cocktail; Thermo Scientific, USA).  Samples 
containing equal protein were separated under reducing conditions using SDS-PAGE and the 
proteins transferred to polyvinylidene difluoride membranes (Millipore, UK).  The primary 
antibodies used in this study were anti-phospho-SPHK1 (1:1000; ECM Biosciences, USA), anti-
total SPHK1 (1:1000; Cell Signaling Technology, USA), anti-phospho-AKT (Ser473; 1:1000; Cell 
Signaling Technology, USA), anti-total AKT (1:1000; Cell Signaling Technology, USA), anti-Į-
tubulin (1:10000; Sigma-Aldrich, USA) and anti-ȕ-actin (1:5000; Sigma-Aldrich, USA).  Bound 
antibodies were detected with peroxidase conjugated secondary antibodies and Enhanced 
Chemiluminescence reagents (Advansta, USA).   
 
Transwell migration and invasion assays 
Migration assays were carried out using fibronectin-coated (10 µg/ml) polycarbonate filters (8 µm 
pore size, Transwell, Corning). Cells were incubated in RPMI/0.5% FBS overnight and re-
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suspended in migration buffer [RPMI containing 0.25 mg/ml fatty acid-free human albumin 
(Sigma)]. 1 x 106 cells were plated into the upper chamber and allowed to migrate for 19 hours in 
the presence or absence of S1P (Enzo Life Sciences) in the lower chamber. Migrated cells were 
stained with 0.1% crystal violet and counted in five random fields. For experiments using inhibitors 
of AKT (LY294002; 1PM; Merck, Germany) and S1PR1/S1PR3 (VPC23019; 1PM; Tocris 
Bioscience, USA), the inhibitors were added to the both lower and upper chambers and S1P (5 PM) 
added to the lower chamber. For invasion assays, pre-coated invasion chambers (8 µm pore size, 
BD BioCoat Matrigel) were used and cells allowed to invade for 48 hours. 
 
Knockdown of SPHK1, AKT and S1PR3 
Two SPHK1 shRNA lentiviral plasmids (pLKO.1/shSPHK1_S1, pLKO.1/shSPHK1_S2) and the 
non-targeting (control) shRNA (pLKO.1/NS) were kindly provided by Prof Chee-Onn Leong 
(International Medical University, Malaysia). Briefly, 293T cells were transfected with the lentiviral 
construct using polyethylenimine together with the packaging plasmid (psPAX2) and envelope 
plasmid (pMDG2). At 48 hour post-transfection, the lentivirus-containing supernatant was 
centrifuged and filtered through a 0.45 µm syringe filter. The viral supernatants and polybrene (8 
µg/ml) were then added to plates cultured with NPC cells and incubated for 16 hours. The virus-
containing media were then removed and the cells cultured in RPMI/10% FBS for an additional 48 
hours before selecting the transfected cells with 0.5-1 Pg/ml puromycin. To knockdown AKT and 
S1PR3, pre-designed RNAi SMART pool reagents (AKT1: L-003000-00; S1PR3: LU-005208-00) 
were obtained from Dharmacon (Chicago, IL) and used at 25 nM. 5x104 cells per well were seeded 
into 6-well plates, cultured for 16 hours and then transfected with the relevant siRNA using 
Oligofectamine (Invitrogen, UK).   
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Expression of constitutively active AKT 
The vector carrying a myristoylated form of AKT, 1036 pcDNA3 Myr HA Akt1 (Addgene plasmid 
# 9008) [16], was used to express constitutively active AKT. Cells at 50% confluency were 
transfected with the 1036 pcDNA3 Myr HA Akt1 or the empty vector at a 3:1 FuGENE HD 
transfection reagent (Promega, USA):DNA ratio. Cells were used in Transwell migration assays 24 
hours post-transfection. 
 
RNA in-situ hybridization  
SIPR3 mRNA expression in the NPC specimens was detected by RNAscope 2.0 assay with a 
SIPR3-specific probe (Advanced Cell Diagnostics, Hayward, CA, USA). FFPE tissue and cell 
block sections (ȝP) were deparaffinized in xylene and then dehydrated in a series of ethanol. The 
S1PR3-specific probes were hybridized to the sections, followed by incubation with preamplifier, 
amplifier and label probes. The chromogenic detection procedures were performed according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV6,35H[Sression was assessed by assigning a proportion score and an 
intensity score. The proportion score relates to the percentage of tumour cells with a positive signal 
(0-100). The intensity score represents the average amount of signals in the tumour cells (0, none; 1, 
weak; 2, intermediate; 3, strong). The SIPR3 expression score was the product of the proportion and 
intensity scores, ranging from 0 to 300. 
 
Analysis of microarray data 
Microarray raw data, GSE12452 and GSE34573, were downloaded from GEO and re-analyzed to 
identify genes differentially expressed between micro-dissected NPC tissues and normal 
nasopharyngeal epithelium. Probe level quantile normalisation [17], RMA (robust multi-array 
analysis) [18] and MAS5 detection analyses were performed using the affy package of the 
Bioconductor project (http://www.bioconductor.org). P values and fold changes were calculated 
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using limma [19]. $II\PHWUL[³+*-)RFXVQDDQQRWFVY´ZDVXVHGIRUSUREHVHWDQQRWDWLRQ3UREH
VHWVZLWK³1HJDWLYH6WUDQG0DWFKLQJ3UREHV´ZHUH UHPRYHG'LIIHUHQWLDOO\ H[SUHVVHGJHQHVZHUH
identified using the criteria of fold change > 1.5 and p value < 0.05. 
 
Statistical analyses 
All statistical analyses were performed using SPSS 23.0 for Windows (IBM Inc., USA) or 
GraphPad Prism Version 5 (GraphPad Software Inc., USA). For Q-PCR and migration/invasion 
DVVD\V VWDWLVWLFDO GLIIHUHQFHV EHWZHHQ H[SHULPHQWDO JURXSV ZHUH HYDOXDWHG E\ 6WXGHQW¶V W-test or 
one-way analysis of variance (ANOVA)/'XQQHWW¶VWHVW. A receiver operating characteristic (ROC) 
curve was constructed using S1PR3 expression scores to select the best cut-off point (maximum 
sensitivity and specificity) that is relevant to the patient survival [20]. NPC cases were group into 
cases with low (score 0-45) or high (score 46-200) expression of S1PR3. Kaplan-Meier survival 
analysis was used to correlate survival rates with S1PR3 expression and the survival probability 
differences were compared by log-rank test. p-values < 0.05 were regarded as significant. 
 
Results 
EBV infection of NPC cells increases the expression of SPHK1 
Given that SPHK1, the key enzyme that produces S1P, has been shown to be commonly expressed 
in primary NPC tissues [10], we opted to investigate whether EBV infection could modulate 
SPHK1 levels in NPC cells. We first compared SPHK1 mRNA expression in eight NPC cell lines 
with that in the immortalised nasopharyngeal epithelial cell line NP69. Among the three NPC cell 
lines that expressed significantly higher levels of SPHK1, we had noted that C666-1, the only EBV-
positive NPC cell line, showed an exceptionally high expression of SPHK1 (Figure 1A). We 
subsequently found that SPHK1 mRNA was significantly elevated in six out of seven NPC cell 
lines stably infected with a recombinant EBV (Akata strain) (p<0.01; Figure 1B). After first 
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validating the specificity of antibodies against total and phosphorylated SPHK1 proteins 
(Supplementary Figure 1), we showed that while the increased expression of the total SPHK1 
protein was confirmed in three representative EBV-infected NPC cell lines, the levels of 
phosphorylated SPHK1 protein were also increased in these cell lines (Figure 1C). Next, we 
investigated which EBV gene(s) were responsible for this effect. To do this, we examined SPHK1 
expression in HONE1 cells individually transfected with EBNA1, LMP1 or LMP2A, all of which 
are expressed in NPC in vivo. We found that both the mRNA and protein levels of SPHK1 were up-
regulated by all the three EBV latent genes in HONE1 cells, with the most marked effect in 
LMP2A-expressing cells (Figure 1D). We conclude that EBV infection can up-regulate the 
expression of SPHK1, hence high levels of S1P are likely to be present in EBV-positive NPC cells. 
 
S1P enhances the migration of NPC cells 
Next, we used Transwell assays to investigate the effects of S1P on the migration of NPC cells 
using three representative NPC cell lines (TW04, HONE1 and SUNE1). We found that the 
exogenous addition of S1P significantly increased the migration of all three cell lines (p<0.001; 
Figure 2A). Given that C666-1 cells do not migrate in Transwell assays, even in the presence of 
10% FBS or S1P, we performed wound healing assays using charcoal-stripped FBS. Similarly, S1P 
enhanced C666-1 cell migration (Supplementary Figure 2). S1P also promoted the invasion of 
SUNE1 cells (Supplementary Figure 3).  We next measured migration in HONE1 cells following 
their transduction with two different shRNAs targeting SPHK1 (shSPHK1_S1 or shSPHK1_S2), or 
with a non-targeting shRNA (NS), as a control. Although C666-1 expressed the highest levels of 
SPHK1 among all the NPC cell lines analysed (Figure 1A), they do not migrate under serum-free 
conditions, even in the presence of S1P (data not shown). Therefore, HONE1 cells were selected for 
these experiments. Reduced expression of both SPHK1 mRNA and protein in transfected HONE1 
was confirmed by Q-PCR and western blot analyses, respectively (Figure 2B). In line with the data 
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that S1P induced NPC cell migration, knockdown of SPHK1 expression suppressed the migration 
of HONE1 cells (p<0.001; Figure 2C).   
 
S1P induces NPC cell migration through activation of AKT 
We next investigated the mechanism of S1P-induced migration of NPC cells. We focussed on the 
AKT pathway because AKT has been shown to be a central player in mediating the oncogenic 
effects of S1P and its activation promotes cancer cell migration in various solid tumour types [7]. 
Secondly, activation of the PI3K/AKT pathway is a common feature of NPC and this pathway is 
stimulated by the EBV-encoded LMP1 or LMP2A genes to promote the migration and invasion of 
NPC cells [21]. We found that the addition of exogenous S1P activated AKT in both HONE1 and 
TW04 cells (Figure 3A). To determine if the activation of AKT by S1P was responsible for the 
increased migration, we treated NPC cells with a PI3K/AKT inhibitor, LY294002. After first 
confirming the inhibitory effects of LY294002 on AKT phosphorylation (Supplementary Figure 4), 
we showed that treatment of HONE1 and SUNE1 with LY294002 led to a significant reduction in 
cell migration in the presence of S1P (p<0.001; Figure 3B). Similarly, knockdown of AKT with a 
pool of four siRNAs targeting AKT significantly suppressed the migration of both HONE1 and 
SUNE1 cell lines (p<0.001; Figure 3C). In keeping with these observations, the knockdown of 
SPHK1 also resulted in a significant reduction in the levels of activated AKT in HONE1 cells 
(Figure 3D). Furthermore, the expression of a constitutively active AKT was able to rescue the 
repressive effects of SPHK1 knockdown on cell migration (p<0.001; Figure 3E). Taken together, 
our results show that S1P induces the migration of NPC cells through the activation of AKT. 
 
Over-expression of S1PR3 in NPC 
We next explored which S1P receptors might be responsible for mediating the S1P-induced 
migration of NPC cells. Re-analyses of two published microarray datasets, GSE12452 [22] and 
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GSE34573 [23], revealed significant and consistent up-regulation of S1PR3 mRNA expression in 
micro-dissected NPC cells compared to normal epithelium (p<0.05; Figure 4A). Expression of the 
other four S1P receptor genes was either not significantly different or not consistently altered in 
both datasets (Supplementary Table 2). We attempted to examine the expression and cellular 
localisation of S1PR3 protein in primary NPC tissues using immunohistochemistry, however, none 
of the three anti-S1PR3 antibodies tested were suitable. Therefore, we opted to use sensitive RNA 
in situ hybridization (RNAscope) to examine the expression of S1PR3 in C666-1 cells, four EBV-
positive NPC patient-derived xenografts (xeno-666, xeno-2117, C15 and C17), an independent 
cohort of 21 formalin-fixed, paraffin-embedded primary NPCs and nine non-malignant 
nasopharyngeal samples. We showed that C666-1 cells, xeno-666 and C15 demonstrated strong 
staining for S1PR3, while weak expression was observed in xeno-2117 and C17 (Figure 4B). In 
tissue samples, normal surface epithelium and epithelium adjacent to the carcinoma were 
consistently negative, whereas S1PR3 expression was detected in 13 of 21 (62%) of the primary 
NPCs examined (Figure 4C).  
 
S1P mediates migration of NPC cell by activating AKT through S1PR3 
Having shown that S1PR3 is over-expressed in primary NPC, we next wanted to determine if this 
receptor was involved in the activation of AKT and increased migration of NPC cells. To do this, 
we first treated two NPC cell lines that express S1PR3 (HONE1 and SUNE1; Supplementary 
Figure 5) with a S1PR1/S1PR3 antagonist, VPC23019. We found that VPC23019 decreased the 
migration of both cell lines in the presence of S1P (p<0.001; Figure 5A). Next, we transfected 
SUNE1 cells with a pool of four siRNAs targeting S1PR3 and the reduced expression of S1PR3 
was confirmed by Q-PCR analysis (Figure 5B). We observed that knockdown of S1PR3 reduced 
the levels of activated AKT (Figure 5C) and partially suppressed the migration of SUNE1 cells in 
the presence of S1P (p<0.001; Figure 5D). To further confirm these effects, we co-transfected 
SUNE1 cells with a constitutively active AKT and S1PR3 siRNAs. Expression of a constitutively 
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active AKT restored the migration of these cells (p<0.001; Figure 5E). We conclude that S1P 
enhances the migration of NPC cells via the activation of AKT by S1PR3.    
 
Discussion 
S1P signalling affects many processes involved in carcinogenesis and there is now a growing 
appreciation that the oncogenic effects of S1P are dependent on the enzymes that generate or 
degrade S1P, and/or alterations in the expression of S1P receptors [7, 11]. Thus, the 
SPHK/S1P/S1PRs axis has become an attractive therapeutic target in cancer. Two functional SPHK 
isoforms, SPHK1 and SPHK2, have been identified in humans [24]. Whilst the role of SPHK2 in 
carcinogenesis remains to be fully explored, the tumour-promoting role of SPHK1 is well 
acknowledged [25]. Indeed, over-expression of SPHK1 has been reported in various types of 
cancer, including NPC [10, 25]. A wide variety of stimuli, including growth factors, GPCR 
agonists, cytokines, phorbol esters, and vitamin D3, can increase SPHK1 levels [26]. In the present 
study, we have identified a novel role for EBV in stimulating the expression and activation of 
SPHK1 in NPC cell lines. Although the mechanisms by which the EBV-encoded genes up-regulate 
the transcription of SPHK1 are yet to be determined, LMP1 and LMP2A are known to activate the 
ERK-MAPK pathway in NPC [27] and this, in turn, would likely result in the phosphorylation of 
SPHK1.  
 
High expression of SPHK1 increases the production of S1P and elevated levels of S1P 
promotes a number of malignant phenotypes associated with cancer cells, including proliferation, 
migration, invasion and angiogenesis [7]. Focussing on the migratory phenotype, our data 
convincingly show that S1P promotes the migration of NPC cells through the activation of AKT, 
and these effects were reversed by the knockdown of SPHK1. We further show that S1P activates 
AKT specifically via S1PR3 to promote the migration of NPC cells. Significantly, the PI3K/AKT 
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signalling pathway is frequently activated in NPC [21]. There is large body of evidence to show that 
S1P-induced migration of cancer cells is dependent upon the expression pattern of S1P receptors 
[28]. S1PR1 and S1PR3 have been shown to stimulate cell migration by coupling to Gi to activate 
Rac through PI3K; although S1PR2 is generally thought to inhibit cell migration via G12/13, we 
recently showed that S1PR2 contributes to the S1P-induced migration of oral cancer cells [29]. The 
involvement of S1PR3-mediated AKT activation in S1P-induced migration has previously been 
inferred indirectly, in a limited number of studies. For example, S1P activated AKT in endothelial 
cells, ovarian cancer cells and thyroid cancer cells and treatment of these cells with LY294002 or 
wortmannin suppressed S1P-induced migration in a Gi-dependent manner [30-32]. Although these 
studies used the S1PR1/3 inhibitor, VPC23019, to reveal the possible involvement of S1PR1 and 
S1PR3 in mediating these effects, it was not clear which receptor was precisely responsible. Similar 
observations were reported in breast cancer cells, but here, S1P induced migration was mediated 
through GDq [33]. Although knockdown of GDq or S1PR3 inhibited AKT phosphorylation, the 
authors did not provide a direct role for S1PR3 in mediating the migration of breast cancer cells 
through AKT. Therefore, we are the first to demonstrate that S1PR3 stimulates cell migration via 
the activation of AKT. 
 
The pro-migratory feature of S1PR3 was also reported to be mediated through the 
accumulation of phosphorylated ERK1/2 into membrane ruffles/lamellipodia and the nucleus of the 
breast cancer cell line, MCF-7 [34]. In the present study, S1P induced the phosphorylation of ERK 
in NPC cells; however, knockdown of SPHK1 did not affect the levels of phosphorylated ERK 
(data not shown). Nonetheless, we cannot rule out the possibility that S1PR3 can also mediate the 
S1P-induced migration of NPC cells through mechanisms other than AKT activation. S1P/S1PR3 
signalling has been shown to promote cancer cell migration/invasion by up-regulating the 
expression of epidermal growth factor receptor (EGFR), hypoxia-induced factor-1 (HIF-1) or C-
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reactive protein (CRP) [35-37]. The identification of effector(s) downstream of S1P/S1PR3/AKT 
signalling that stimulate the migration of NPC cells warrants further investigation. Further, we 
noted that knockdown of S1PR3 did not completely suppress the S1P-induced migration in SUNE1 
cells. There are two possible reasons to explain these observations; one is the incomplete 
knockdown of S1PR3, and the second, another S1P receptor(s) might also be involved. Given that 
the up-regulation of S1PR5 was demonstrated in one of the microarray studies (Table S2), the 
involvement of this receptor in S1P-induced migration of NPC cells cannot be ruled out. Although 
the role of S1PR5 in tumorigenesis is still uncertain, it remains a possibility that by coupling to Gi, 
S1PR5 can trigger Rac that lead to an increase in NPC cell migration. 
 
It has been shown that SPHK1 and S1PR3 function in an amplification loop to promote the 
migration of breast cancer cells [34]. However, we did not observe any consistent changes in 
S1PR3 expression following either knockdown of SPHK1 or EBV infection of NPC cells (data not 
shown). Since C15 is the only NPC xenograft that expresses LMP1, the high expression of S1PR3 
in C15 prompted us to investigate whether LMP1 could modulate S1PR3 expression. However, of 
the 19 tumours in this series that were also stained for LMP1, we did not observe a correlation 
between S1PR3 and LMP1 expression (data not shown). Therefore, the mechanisms that regulate 
S1PR3 expression in NPCs remain to be determined and our data suggest that the expression of 
SPHK1 and S1PR3 in NPC cells are regulated by different mechanisms. Irrespective of these 
differences, high levels of SPHK1 in NPCs have been correlated with poor patient prognosis [10] 
and high expression of S1PR3 in the present study is associated with a worse overall survival in 
NPC patients (p<0.05; Supplementary Figure 6), data that are in line with those of Watson and 
colleagues who reported an association between high S1PR3 expression and shorter disease-specific 
survival in breast cancer patients [38].  
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In summary, we report for the first time that S1P is likely produced by NPC cells through the 
up-regulation of SPHK1 following EBV infection, and that S1P contributes to a migratory 
phenotype of NPC cells by activating AKT through S1PR3. Our data highlight the potential of 
targeting of SPHK1/S1P/S1PR3 axis in NPC patients. 
 
Acknowledgement 
This research is supported by High Impact Research Grant UM.C/625/1/HIR/MOHE/DENT/23 
from the University of Malaya. KW Lo is supported by Hong Kong RGC TRS: T12-401/13-R. We 
gratefully thank Prof Chee-Onn Leong for providing the SPHK1 shRNA plasmids. 
 
Author contributions 
LFY, ICP and PGM conceived and designed the study; HML, KWL, GTYC, MHI performed 
experiments; WW performed microarray data analyses; SWT and CWD produced transfected cell 
lines; ICP, PGM and CWD critically reviewed the manuscript and contributed intellectual opinion; 
LFY and ICP supervised the study. LFY and HML wrote the manuscript. All authors reviewed the 
manuscript. 
 
References 
1. Razak AR, Siu LL, Liu FF, et al. Nasopharyngeal carcinoma: the next challenges. Eur J 
Cancer 2010; 46: 1967-1978. 
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 
65: 87-108. 
3. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic 
developments. Expert Rev Mol Med 2007; 9: 1-24. 
4. Chua ML, Wee JT, Hui EP, et al. Nasopharyngeal carcinoma. Lancet 2015. 
5. Du CR, Ying HM, Kong FF, et al. Concurrent chemoradiotherapy was associated with a 
higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with 
radiotherapy alone: a meta-analysis based on randomized controlled trials. Radiat Oncol 
2015; 10: 70. 
6. Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer 
2014; 33: 581-590. 
7. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503. 
16 
 
8. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem 
Sci 2011; 36: 97-107. 
9. Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-
mediated phosphorylation. EMBO J 2003; 22: 5491-5500. 
10. Li W, Tian Z, Qin H, et al. High expression of sphingosine kinase 1 is associated with poor 
prognosis in nasopharyngeal carcinoma. Biochem Biophys Res Commun 2015; 460: 341-
347. 
11. Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid 
Res 2014; 55: 1596-1608. 
12. Yap LF, Velapasamy S, Lee HM, et al. Down-regulation of LPA receptor 5 contributes to 
aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma. J Pathol 2015; 235: 
456-465. 
13. Huang DP, Ho JH, Chan WK, et al. Cytogenetics of undifferentiated nasopharyngeal 
carcinoma xenografts from southern Chinese. Int J Cancer 1989; 43: 936-939. 
14. Cheung ST, Huang DP, Hui AB, et al. Nasopharyngeal carcinoma cell line (C666-1) 
consistently harbouring Epstein-Barr virus. Int J Cancer 1999; 83: 121-126. 
15. Busson P, Ganem G, Flores P, et al. Establishment and characterization of three 
transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988; 42: 599-606. 
16. Ramaswamy S, Nakamura N, Vazquez F, et al. Regulation of G1 progression by the PTEN 
tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt 
pathway. Proc Natl Acad Sci U S A 1999; 96: 2110-2115. 
17. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for 
high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 
185-193. 
18. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high 
density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264. 
19. Smyth GK. Linear models and empirical bayes methods for assessing differential expression 
in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3. 
20. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for 
novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60: 
1112-1116. 
21. Tsao SW, Tsang CM, To KF, et al. The role of Epstein-Barr virus in epithelial 
malignancies. J Pathol 2015; 235: 323-333. 
22. Sengupta S, den Boon JA, Chen IH, et al. Genome-wide expression profiling reveals EBV-
associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 
2006; 66: 7999-8006. 
23. Hu C, Wei W, Chen X, et al. A global view of the oncogenic landscape in nasopharyngeal 
carcinoma: an integrated analysis at the genetic and expression levels. PLoS One 2012; 7: 
e41055. 
24. Liu H, Chakravarty D, Maceyka M, et al. Sphingosine kinases: a novel family of lipid 
kinases. Prog Nucleic Acid Res Mol Biol 2002; 71: 493-511. 
25. Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health 
and disease: Recent advances. Prog Lipid Res 2016; 62: 93-106. 
26. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000; 
349: 385-402. 
27. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent membrane proteins 
LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer 
Biol 2012; 22: 144-153. 
28. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell 
migration by the Edg family sphingosine-1-phosphate receptors. Biochim Biophys Acta 
2002; 1582: 112-120. 
17 
 
29. Patmanathan SN, Johnson SP, Lai SL, et al. Aberrant expression of the S1P regulating 
enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated 
through S1PR2. Sci Rep 2016; 6: 25650. 
30. Morales-Ruiz M, Lee MJ, Zollner S, et al. Sphingosine 1-phosphate activates Akt, nitric 
oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway 
in endothelial cells. J Biol Chem 2001; 276: 19672-19677. 
31. Balthasar S, Samulin J, Ahlgren H, et al. Sphingosine 1-phosphate receptor expression 
profile and regulation of migration in human thyroid cancer cells. Biochem J 2006; 398: 
547-556. 
32. Park KS, Kim MK, Lee HY, et al. S1P stimulates chemotactic migration and invasion in 
OVCAR3 ovarian cancer cells. Biochem Biophys Res Commun 2007; 356: 239-244. 
33. Kim ES, Kim JS, Kim SG, et al. Sphingosine 1-phosphate regulates matrix 
metalloproteinase-9 expression and breast cell invasion through S1P3-Galphaq coupling. J 
Cell Sci 2011; 124: 2220-2230. 
34. Long JS, Edwards J, Watson C, et al. Sphingosine kinase 1 induces tolerance to human 
epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in 
response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol 
Cell Biol 2010; 30: 3827-3841. 
35. Hsu A, Zhang W, Lee JF, et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates 
epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated 
carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol 2012; 40: 1619-
1626. 
36. Kalhori V, Kemppainen K, Asghar MY, et al. Sphingosine-1-Phosphate as a Regulator of 
Hypoxia-Induced Factor-1alpha in Thyroid Follicular Carcinoma Cells. PLoS One 2013; 8: 
e66189. 
37. Kim ES, Cha Y, Ham M, et al. Inflammatory lipid sphingosine-1-phosphate upregulates C-
reactive protein via C/EBPbeta and potentiates breast cancer progression. Oncogene 2014; 
33: 3583-3593. 
38. Watson C, Long JS, Orange C, et al. High expression of sphingosine 1-phosphate receptors, 
S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is 
associated with development of tamoxifen resistance in estrogen receptor-positive breast 
cancer patients. Am J Pathol 2010; 177: 2205-2215. 
  
18 
 
Figure legends 
 
Figure 1. EBV infection up-regulates the expression of SPHK1. (A) Compared to an immortalised 
nasopharyngeal epithelial cell line (NP69), SPHK1 levels were significantly increased in three 
(C666-1, HONE1 and TW01) out of eight NPC cell lines examined. Among these, C666-1 
expressed the highest levels of SPHK1. (B) Q-PCR analysis showed that the expression of SPHK1 
was significantly up-regulated in six (HK1, CNE1, SUNE1, HONE1, CNE2, TW01) out of seven 
NPC cell lines stably infected with an Akata-derived recombinant EBV. Data are expressed as the 
relative expression between the cells infected with EBV and their respective controls (normalised to 
1). (C) Western blot analysis showed that the protein levels of SPHK1 (both total and 
phosphorylated proteins) were increased in three NPC cell lines (HK1, CNE1 and SUNE1) 
following EBV infection. (D) Q-PCR and western blot analyses showed that both the mRNA and 
protein levels of SPHK1 were higher in HONE1 cells expressing specific EBV latent genes 
(EBNA1, LMP1 or LMP2A) compared with the vector control cells. ***p<0.001.  
 
Figure 2. S1P promotes NPC cell migration. (A) TW04, HONE1 and SUNE1 cells were allowed to 
migrate through fibronectin-FRDWHGPHPEUDQHVLQWKHDEVHQFHRUSUHVHQFHRI63RUȝ063
significantly enhanced the migration of all three cell lines. (B) HONE1 cell stably transduced with 
two independent shRNAs (shSPHK1_S1 or shSPHK1_S2) or a non-targeting shRNA (NS). Upper 
left panel: Q-PCR analysis confirmed the reduced levels of SPHK1 mRNA in SPHK1 shRNA-
transfected cells. The expression of SPHK1 in NS (control) cells was normalised to 1.  Lower left 
panel: A representative Western blot showing decreased expression of both total and 
phosphorylated SPHK1 proteins in cells transfected with SPHK1 shRNAs. Densitometric data 
(right panels) are expressed as the mean relative density (normalised to D-tubulin) ±SD from three 
independent experiments. (C) SPHK1 knockdown significantly suppressed migration of HONE1 
cells.  Data for the migration assays are expressed as the mean percentage of cells migrating ±SD 
and the results are expressed relative to the migration of the control cells (=100%). *p<0.05; 
**p<0.01; ***p<0.001. 
 
Figure 3. S1P promotes migration of NPC cells by activating AKT. (A) Western blot analyses 
showed that AKT was activated (assessed by AKT phosphorylation) in HONE1 and TW04 cells 
IROORZLQJH[RJHQRXVDGGLWLRQRIȝ063%7UDQVZHOOPLJUDWLRQDVVD\VRI+21(DQG681(
FHOOV LQ WKH DEVHQFH RU SUHVHQFH RI 63 ȝ0 LQ WKH ORZHU FKDPEHU DQG D 3,.AKT inhibitor 
/<ȝ0LQERWKWKHXSSer and lower chambers. Treatment with LY294002 significantly 
inhibited the S1P-induced migration of these two NPC cell lines. (C) Knockdown of AKT using a 
pool of four siRNAs targeting AKT significantly suppressed the migration of both HONE1 and 
SUNE1 cell lines. (D) Upper panel: Western blotting analysis showed that knockdown of SPHK1 in 
HONE1 cells using two independent shRNAs (shSPHK1_S1 or shSPHK1_S2) suppressed the 
activation of AKT compared to the control (NS). Densitometric data (lower panels) are expressed as 
the mean relative density (normalised to D-tubulin) ±SD from three independent experiments. (E) 
Transfection of a constitutively active AKT in SPHK1-knockdown HONE1 cells restored the 
migration of these cells. Data for the migration assays are expressed as mean percentage of cells 
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migrating ±SD and the results are expressed relative to the migration of control cells (=100%). 
*p<0.05; **p<0.01; ***p<0.001. 
 
Figure 4. Over-expression of S1PR3 in NPC. (A) Two microarray datasets (GSE12452 and 
GSE34573) showed that S1PR3 mRNA was significantly upregulated in micro-dissected NPC cells 
compared with normal epithelium (p<0.05). (B) RNAscope analysis of S1PR3 expression in NPC-
derived EBV-positive cell line and xenografts. [a-c] C666-1, xeno-666 and C15 demonstrating 
strong S1PR3 signals (red arrows) (magnification: x400); [d, e] Weak expression of S1PR3 was 
detected in xeno-2117 and C17. (C) RNAscope analysis confirms over-expression of S1PR3 in 
primary NPC tissues. [a, b] Two separate examples of normal epithelium demonstrating negative 
staining. Representative NPC cases showing [c] negative, [d] weak and [e, f] strong expression of 
S1PR3 in the carcinoma (red arrows) (magnification: X400). 
 
Figure 5. S1P induces NPC cell migration through AKT activation via S1PR3. (A) Transwell 
PLJUDWLRQDVVD\VRI+21(DQG681(FHOOVLQWKHDEVHQFHRUSUHVHQFHRI63ȝ0LQWKHORZHU
FKDPEHUDQGD635635DQWDJRQLVW93&ȝ0LQERWKWKHXSSHUDQGORZHUFKDPEHUV
S1P-induced migration was markedly suppressed in both cell lines following treatment with 
VPC23019. (B) SUNE1 cells were transfected with 25nM of a pool of siRNAs targeting S1PR3 
(siS1PR3) or non-targeting random siRNAs (NT) for 48 and 72 hours. QPCR-analysis confirmed 
the knockdown of S1PR3 in SUNE1 cells. SUNE1 cells transfected with NT siRNAs were 
normalized to 1. (C) The levels of phosphorylated AKT were reduced in SUNE1 cells following 
S1PR3 knockdown. (D) Migration of SUNE1 cells following S1PR3 knockdown in Transwell 
assays iQWKHDEVHQFHRUSUHVHQFHRI63ȝ0,QKLELWLRQRI635VLJQLILFDQWO\VXSSUHVVHGWKH
migration of SUNE1 cells accompanied by a decrease in AKT phosphorylation. (E) Transwell 
assays of transient transfection of S1PR3-knockdown SUNE1 cells with a constitutively active 
AKT or the empty vector. The expression of a constitutively active AKT significantly restored the 
migration of S1PR3-knockdown SUNE1 cells. Data for Transwell migration assays are expressed 
as mean percentage of cells migrating ±SD relative to migration of the control cells (=100%). 
**p<0.01; ***p<0.001. 
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Legends for Supporting Information 
)LJXUH69DOLGDWLRQRIWKHVSHFLILFLW\RIDQWLERGLHVDJDLQVWWRWDORUSKRVSKRU\ODWHG63+.SURWHLQ
$GLVWLQFWEDQGFRUUHVSRQGLQJ WR WKHSUHGLFWHGPROHFXODUZHLJKWRI63+.SURWHLQN'DZDV
HYLGHQWLQ+(.FHOOVWUDQVIHFWHGZLWKD63+.FRQVWUXFWS&09B;/63+. 
 
Figure S2 S1P promotes migration of C666-1 cells in wound healing assays. The effect of S1P on 
C666-1 cell migration was examined in wound healing assays using charcoal-stripped FBS 
(Biowest, France). Left panel: Representative images showing enhanced migration of C666-1 cells 
in the presence of S1P at 24 hour. Right panel: Images were analysed using WimScratch (Wimasis 
Image Analysis) and the data are expressed relative to the wound area at 0 hour (=100%). *p<0.05. 
 
)LJXUH 6 63 HQKDQFHV LQYDVLRQ RI 681( FHOOV LQ YLWUR 7KH LQYDVLYH DELOLW\ RI 681( ZDV
H[DPLQHGLQSUH-FRDWHGLQYDVLRQFKDPEHUVPSRUHVL]H%'%LR&RDW0DWULJHOLQWKHSUHVHQFH
RI63LQWKHORZHUFKDPEHU 
 
)LJXUH6&RQILUPDWLRQRIWKHLQKLELWLRQRI$.7DFWLYDWLRQIROORZLQJWUHDWPHQWZLWKD3,.$.7
LQKLELWRU/<:HVWHUQEORWWLQJDQDO\VHVRI681(FHOOVWUHDWHGZLWK0/<RUWKH
YHKLFOHFRQWUROIRUKRXUV 
 
)LJXUH 6 ([SUHVVLRQ SURILOHV RI 63 UHFHSWRUV LQ +21( DQG 681( FHOOV $OO ILYH UHFHSWRUV
ZHUHGHWHFWHGLQERWKFHOOOLQHV 
 
 
)LJXUH 6 Kaplan Meier survival analysis revealed higher expression of S1PR3 correlated with 
poor patient survival (p<0.05).   
 
7DEOH6&OLQLFDOFKDUDFWHULVWLFVRISULPDU\13&VDPSOHV 
 
Table S2 Summary of the mRNA expression of five S1P receptors in NPC cells. For each probe set 
on the microarray corresponding to each of the S1P receptor, we recorded the number of NPC and 
QRUPDO VDPSOHV LQZKLFKD ³SUHVHQW´ FDOOZDV PDGH ZKLFKSURYLGHV DQ LQGLFDtion of expression 
above an arbitrary threshold). We also performed a statistical test to determine if the level of 
expression for each probe set was significantly different between NPC samples and normal controls. 
Data from pUREH VHWV WKDW \LHOGHG ³DEVHQW´ FDOOV LQ DOO VDPSOHV ZHUH considered not valid. 
Significant change was defined as fold change > 1.5 with a p value < 0.05. Only S1PR3 was 
significantly up-regulated in both microarray datasets. NA, not available. 
 
 
